Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain enGene (
NASDAQ:ENGN ) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
On a company call, President and
This Biotech Was Quietly Bought Before a $58 Per Share Takeout This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Let's take a look at the stocks that are in motion in today's session. Curious about what's happening in today's session? Check out the latest stock movements and price changes.
EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.
Let's uncover which stocks are experiencing notable gaps during today's session. The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
ENGN Stock Soars On Hopeful Data From Bladder Cancer Study The company is now looking forward to submitting an application for approval of the cancer therapy to the U.S. Food and Drug Administration in the second half of 2026.
Get insights into the top gainers and losers of Tuesday's pre-market session. Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
enGene Holdings Inc (NASDAQ:ENGN) Posts Wider-Than-Expected Q3 Loss as R&D Spending Doubles enGene posts wider-than-expected Q3 loss as R&D spending doubles. The biotech advances its pivotal LEGEND trial and secures key FDA RMAT designation.
